Format

Send to

Choose Destination
J Steroid Biochem Mol Biol. 2018 Sep;182:4-13. doi: 10.1016/j.jsbmb.2018.04.005. Epub 2018 Apr 19.

Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain).

Author information

1
National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
2
Department of Analytical Chemistry, University of Córdoba, Spain; Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofía University Hospital, University of Córdoba, Spain.
3
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research institute, San Sebastian, Spain.
4
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Spain.
5
Área de Medicina Preventiva y Salud Pública, Departamento de Ciencias Biomédicas, Universidad de León, León, Spain; Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Universidad de León, León, Spain.
6
Early Detection Section, Public Health Institute of Navarra, Pamplona, Spain.
7
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; University of Cantabria - IDIVAL, Santander, Spain.
8
IUOPA, University of Oviedo, Oviedo, Spain.
9
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
10
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi), Girona, Spain.
11
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Campus de Bellvitge, L'Hospitalet del Llobregat, Spain; Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Spain.
12
Valencia Breast Cancer Screening Program, General Directorate Public Health, Valencia, Spain.
13
Universidad de Huelva, Huelva, Spain; Centro de Investigación en Salud y Medio Ambiente (CYSMA), Huelva, Spain.
14
Public Health Division of Gipuzkoa, BioDonostia Research institute, San Sebastian, Spain.
15
Center for Research on Population Health, National Institute of Public Health, Mexico; Hubert Department of Global Health, Emory University, Atlanta, GA, USA.
16
National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain. Electronic address: mpollan@isciii.es.

Abstract

Epidemiologic evidence on the association between vitamin D and breast cancer is still inconclusive. This study analyzes the association between serum 25-hydroxyvitamin D (25(OH)D) and breast cancer risk by pathologic subtype, stage at diagnosis and specific breast cancer risk factors. We conducted a population-based multicase-control study where 546 histologically-confirmed breast cancer cases and 558 population controls, frequently matched by geographic area, age and body mass index, were recruited in 12 Spanish provinces (MCC-Spain). Information was collected by a questionnaire and plasma 25(OH)D was measured by solid-phase extraction on-line coupled to liquid chromatography-tandem mass spectrometry (SPE-LC-MS/MS). Odds ratios and 95% confidence intervals were calculated using logistic and multinomial mixed regression models. We found a clear protective effect between 25(OH)D levels and breast cancer risk, with a significant dose-response trend (OR per 10 nmol/L = 0.88; 95%CI = 0.82-0.94). While no differences were observed between pre and postmenopausal women, stage at diagnosis, or across strata of the main breast cancer risk factors, the protection was more pronounced for triple negative tumors (OR per 10 nmol/L = 0.64; p-heterogeneity = 0.038). Similar results were observed when only cases sampled in the first month after diagnosis were considered. The protective effect of vitamin D on breast cancer risk may be subtype specific, being stronger for more aggressive tumors, which provides a new approach to prevent this disease.

KEYWORDS:

25(OH)D; Breast neoplasm; Calcidiol; Stage at diagnosis; Triple negative tumor; Vitamin D

PMID:
29679754
DOI:
10.1016/j.jsbmb.2018.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center